REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study (Revolution)
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results. There is a subgroup of patients with peripheral nonperfusion on ultrawidefield angiography that appears to be more dependent on anti-VEGF treatment.
In this trial the investigators compare the gold standard of monthly ranibizumab injections with ranibizumab + peripheral scatter laser to the areas of nonperfusion on angiography. Each group will have monthly injections for the first six months, then as needed by either visual acuity decrease or increased retinal thickness for the subsequent six months.
The primary outcome is visual acuity. Secondary outcomes are reduction in optical coherence tomography, and number of ranibizumab injections
Branch Retinal Vein Occlusion
Procedure: Peripheral Laser
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II|
- Visual Acuity [ Time Frame: 6 and 12 months ]ETDRS visual acuity
- Number of Ranibizumab Injections [ Time Frame: 12 months ]Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in second six months of observation period
- Retinal Thickness [ Time Frame: 6 and 12 months ]central foveal thickness on optical coherence tomography
|Study Start Date:||November 2010|
|Study Completion Date:||May 2014|
|Primary Completion Date:||May 2014 (Final data collection date for primary outcome measure)|
Experimental: Peripheral Laser + Ranibizumab
Angiography-directed peripheral laser + ranibizumab
Intravitreal Ranibizumab 0.5 mg
Other Names:Procedure: Peripheral Laser
Angiography-directed peripheral laser
Active Comparator: Ranibizumab
Intravitreal Ranibizumab 0.5 mg
Hide Detailed Description
SUBJECTS Subject Selection Twenty subjects from a single site in the United States will be enrolled. Eligible subjects will have provided informed consent. (See Appendix A, the study flow chart, for screening assessments.)
Subjects will be eligible if the following criteria are met:
Ability to provide written informed consent and comply with study assessments for the full duration of the study Age > 18 years
Disease related considerations:
Study eye with macular edema secondary to branch retinal vein occlusion characterized by:
Fovea-involved macular edema of less than 12 months peripheral nonperfusion defined as at least 5 disc areas of contiguous nonperfusion on ultra-widefield fluorescein angiography absence of macular traction on clinical exam, UWFA, and OCT.
Study eye with best corrected visual acuity between 20/40 (≤ 73 letters on ETDRS chart) and 20/320 (≥ 19 letters on ETDRS chart) Other considerations Patient able to complete all study visits
Subjects who meet any of the following criteria will be excluded from this study:
Pregnancy (positive pregnancy test) or lactation. Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
Prior enrollment in the study Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated Participation in another simultaneous medical investigation or trial Therapy with intravitreal triamcinolone, pegaptanib, ranibizumab, or bevacizumab within the previous 3 months Previous macular or panretinal scatter laser photocoagulation Previous pars plana vitrectomy Visually-significant significant cataracts as primary reason for vision loss Myocardial infarction or cerebrovascular accident within 6 months
METHOD OF TREATMENT ASSIGNMENT Patients meeting the study criteria and providing informed consent will be randomized according to the attached randomization chart (Appendix E) to study or control arm until 10 eyes are assigned to each group. Patients with both eyes eligible for the study will be assigned by coin flip.
STUDY TREATMENT Formulation Ranibizumab is formulated as a sterile solution aseptically filled in a sterile, 2 mL or 3-mL stoppered glass vial. Each single use vial is designed to deliver 0.05 mL of 10 mg/mL ranibizumab aqueous solution with 10 mM histidine HCI, 10%, trehalose dihydrate, and 0.01% polysorbate 20, pH 5.5. Each vial contains no preservative and is suitable for single use only.
Further details and molecule characterization will be included in the Investigator Brochure.
Dosage, Administration, and Storage
- Dosage Patients in the treatment and control arms will receive intravitreal injection of 0.5 mg ranibizumab on the screening/Day 0 visit, and months 1 - 5. The need for subsequent injections at months 6 - 11 will be determined by presence of persistent or recurrent intraretinal fluid on OCT evaluation.
Storage Upon receipt, study drug kits should be refrigerated at 2C - 8C (36F - 46F). DO NOT FREEZE. Do not use beyond the expiration date. Ranibizumab vials should remain refrigerated. Protect vials from direct sunlight. Store in original carton until time of use.
RANIBIZUMAB VIALS ARE FOR SINGLE USE ONLY. Vials used for one subject may not be used for any other subject.
CONCOMITANT AND EXCLUDED THERAPIES Subjects may continue to receive all medications and standard treatments administered for their conditions at the discretion of their treating physician.
STUDY ASSESSMENTS Assessments during the Treatment Period Screening / Day 0 Visit Informed consent Demographic data Medical and ocular history Vital signs (BP, heart rate) Pregnancy test (if applicable) Best corrected visual acuity (BCVA) ETDRS chart Slit lamp examination Intraocular pressure Dilated fundus examination Optical Coherence Tomography UWFA Ranibizumab treatment + peripheral laser tx (Treatment group) Ranibizumab treatment (Comparative group) SAE Monitoring Post-injection Phone Follow-up Update medical and ocular history SAE Monitoring Months 1, 2, 3, 4, and 5 Visits Update medical and ocular history Vital signs Best corrected visual acuity (BCVA) ETDRS chart Slit lamp examination Intraocular pressure Dilated fundus examination UWFA (Month 3) Ranibizumab treatment (Treatment and Comparative group) Optical Coherence Tomography SAE monitoring Month 6 Visit Update medical and ocular history Vital signs Best corrected visual acuity (BCVA) ETDRS chart Slit lamp examination Intraocular pressure Dilated fundus examination Optical Coherence Tomography UWFA SAE monitoring Months 6, 7, 8, 9, 10, 11, and 12 Visits Update medical and ocular history Vital signs Best corrected visual acuity (BCVA) ETDRS chart Slit lamp examination Intraocular pressure Dilated fundus examination Optical Coherence Tomography Ranibizumab treatment if necessary as determined by Optical Coherence Tomography assessment (Treatment and Comparative group) SAE monitoring
Early Termination Assessments Subjects who withdraw from the study prior to completion should return for an early termination evaluation 30 days (14 days) following the last injection/study visit for monitoring of all adverse events (serious and nonserious). The schedule of assessments for early termination is the same as that for the final visit.
SUBJECT DISCONTINUATION Subjects have a right to withdraw from the study at any time. The subject may be withdrawn from the study for any reasons: if it is in the best interest of the subject, intercurrent illness, adverse events, or worsening condition. The Western IRB may request the withdrawal of a subject because of protocol violations, administrative reasons, or any other valid and ethical reasons.
If a subject discontinues from the study, he or she will not be allowed to re enter the study.
Reasons for subject discontinuation may include, but are not limited to, the following:
Sensory rhegmatogenous retinal detachment or Stage 3 or 4 macular hole Investigator determination that it is not in the best interest of the subject to continue participation Pregnancy Verteporfin PDT treatment in the study eye Pegaptanib sodium injection treatment in either eye Bevacizumab injection in either eye SAE Any other safety concerns In the event of an adverse event in the study eye that is considered by the investigator to be severe in intensity, serious consideration should be given to discontinuing the subject from the study.
This study may be terminated by Western IRB or Retina Associates of Florida at any time. Reasons for terminating the study may include the following:
The incidence or severity of adverse events in this or other studies indicates a potential health hazard to subjects Subject enrollment is unsatisfactory Data recording is inaccurate or incomplete
STATISTICAL METHODS Analysis of the Conduct of the Study There is no formal sample size calculation in this pilot study. As this is a phase I study, a sample size of 30 patients is chosen, making sure that it is feasible financially to conduct the study and logistically to complete the study within 18 months. If and when the study is planned for a phase II randomized control trial, appropriate statistical analysis will be determined.
Safety Analyses Any adverse events, laboratory assessments, physical examinations, vital signs, ocular examinations and measurements from all 30 subjects will be utilized to summarize safety data for this pilot study.
Efficacy Analyses Primary Endpoint Mean change in best corrected visual acuity (BCVA), as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters at Month 6. This will also include eyes with gain of 15 letters or more, or loss of 15 letters or more on the ETDRS eye chart Secondary Endpoints Mean change in best corrected visual acuity (BCVA), as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters at Month 2.
Percent reduction of foveal thickness by optical coherence tomography. Percent reduction of macular volume by optical coherence tomography. Mean number of injections between Months 6 and 12.
Missing Data Analyses of efficacy and safety will be based on available cases, without imputation for missing values.
Interim Analyses No formal schedule of interim analyses is planned. Reports of adverse events from this study may be reviewed and summarized periodically while the study is ongoing to ensure the safety of subjects.
DATA QUALITY ASSURANCE Accurate, consistent, and reliable data will be ensured through the use of standard practices and procedures.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01247220
|United States, Florida|
|Retina Associates of Florida, P.A.|
|Tampa, Florida, United States, 33609|
|Study Chair:||Ivan J Suner, MD||Retina Associates of Florida, P.A.|